BioCryst Pharmaceuticals (MEX:BCRX) Cash-to-Debt : 0.40 (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is BioCryst Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. BioCryst Pharmaceuticals's cash to debt ratio for the quarter that ended in Dec. 2024 was 0.40.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, BioCryst Pharmaceuticals couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for BioCryst Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

MEX:BCRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.4 Med: 1.05 Max: 2.09
Current: 0.4

During the past 13 years, BioCryst Pharmaceuticals's highest Cash to Debt Ratio was 2.09. The lowest was 0.40. And the median was 1.05.

MEX:BCRX's Cash-to-Debt is ranked worse than
65.47% of 1005 companies
in the Drug Manufacturers industry
Industry Median: 1.02 vs MEX:BCRX: 0.40

BioCryst Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for BioCryst Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

BioCryst Pharmaceuticals Cash-to-Debt Chart

BioCryst Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

Get a 7-Day Free Trial

1.08

0.86

0.57

0.47

0.40

BioCryst Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial															0.47	0.41	0.33	0.41	0.40

Competitive Comparison of BioCryst Pharmaceuticals's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, BioCryst Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioCryst Pharmaceuticals's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioCryst Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

BioCryst Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

BioCryst Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	6691.551	/	(57.812	+	16809.069)
	=	0.40

BioCryst Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	6691.551	/	(57.812	+	16809.069)
	=	0.40

BioCryst Pharmaceuticals (MEX:BCRX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

BioCryst Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

BioCryst Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioCryst Pharmaceuticals Inc (MEX:BCRX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

BCRX:USA BO1:Germany

Address

4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703

Website

https://www.biocryst.com

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.